Ovid Therapeutics Inc. (OVID)
NCM · Healthcare · Biotechnology
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
About Ovid Therapeutics Inc.
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia. It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 132K | 718K | 0.00 | 733K |
| Operating Income | (12.5M) | (12.3M) | (17.8M) | (15.7M) |
| Net Income | (12.2M) | 9.7M | (17.0M) | (15.0M) |
| Diluted EPS | $-0.17 | $0.06 | $-0.12 | $-0.08 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 1.5M | 392K | 566K | 7.3M |
| Operating Income | (55.5M) | (59.3M) | (61.9M) | (42.4M) |
| Net Income | (54.2M) | (52.3M) | (26.4M) | (17.4M) |
| Diluted EPS | $-0.77 | $-0.73 | $-0.37 | $-0.23 |